Pfizer Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Albert Bourla
- Full Time Employees
- 75,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 66 Hudson Boulevard East New York City NY United States of America 10001-2192
- IPO Date
- Jun 1, 1972
- CIK
- 0000078003
- Website
- pfizer.com
- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Company News
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive
How Much Do You Need Invested to Collect $8,450 a Month for Life?
Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
6 High-Yield Stocks Where the Market May Be Warning of a Dividend Cut
Treasury Yields Are Above 5%. These 4 Dividend Stocks Still Make the Cut
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap?
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs